Real-life versus package insert: A post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers

Vaccine

Volumn 29, Issue 31, 2011, Pages 5000-5006

  Hatz, Christoph ^a,b   Beck, Bernhard ^a,b   Steffen, Robert ^b   Genton, Blaise ^a,c   d'Acremont, Valérie ^a,c   Loutan, Louis ^d   Hartmann, Katharina ^e   Herzog, Christian ^e  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Adverse events; Hepatitis A vaccine; Safety; Self reporting; Virosomal vaccine

Indexed keywords

HEPATITIS A VACCINE; VIROSOME VACCINE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ANOREXIA; ARTICLE; CHILD; DIARRHEA; DIZZINESS; DRUG PACKAGING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEPATITIS A; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SELF REPORT; SEX RATIO; SINGLE DRUG DOSE; TRAVEL; VOMITING;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRODUCT LABELING; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; YOUNG ADULT;

EID: 79959756256     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.099     Document Type: Article

References (26)

1. Lopez-Velez R., Bayas J.M. Spanish travelers to high-risk areas in the tropics: airport survey of travel health knowledge, attitudes, and practices in vaccination and malaria prevention. J Travel Med 2007, 14:297-305.
2. Nir Y., Paz A., Sabo E., Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 2003, 68:341-344.
3. Ioannidis J.P., Mulrow C.D., Goodman S.N. Adverse events: the more you search, the more you find. Ann Intern Med 2006, 144:298-300.
4. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002, 21:298-302.
5. Bent S., Padula A., Avins A.L. Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006, 144:257-261.
6. Just M., Berger R., Dreschsler H., Brantschen S., Glück R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 1992, 10:737-739.
7. Loutan L., Bovier P., Althaus B., Glück R. Inactivated virosome hepatitis A vaccine. Lancet 1994, 343:322-324.
8. Poovorawan Y., Theamboonlers A., Chumdermpadetsuk S., Glück R., Cryz S.J. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome formulated hepatitis A vaccine in Thais. Vaccine 1995, 13:891-893.
9. Ambrosch F., Wiedermann G., Jonas S., Althaus B., Finkel B., Glück R., et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997, 15:1209-1213.
10. Usonis V., Bakasénas V., Valentelis R., Katiliene G., Vidzeniene D., Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 2003, 21:4588-4592.
11. D'Acremont V., Herzog C., Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med 2006, 13:78-83.
12. Van Der Wielen M., Vertruyen A., Froesner G., Ibáñez R., Hunt M., Herzog C., et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16years. Pediatr Infect Dis J 2007, 26:705-710.
13. Holzer B.R., Hatz C., Schmidt-Sissolak D., Glück R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-absorbed hepatitis A: a randomized controlled trial. Vaccine 1996, 14:982-986.
14. Bovier P.A., Farinelli T., Loutan L. Interchangeability and tolerability of a virosomal and an aluminium-adsorbed hepatitis A vaccine. Vaccine 2005, 23:2422-2427.
15. Clarke P.D., Adams P., Ibanez R., Herzog C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Med Infect Dis 2006, 4:313-318.
16. Epaxal®, Summary of Product Characteristics 2005, Istituto Sieroterapico Berna s.r.l., Como, Italy.
17. De Serres G., Duval B., Boulianne N., Rochette M., Dionne M., Fradet M.D., et al. Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children. Am J Public Health 2001, 91:313-315.
18. Wernicke J.F., Faries D., Milton D., Weyrauch K. Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Saf 2005, 28:1057-1063.
19. Biswas P.N., Wilton L.V., Shakir S.W. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens 2002, 16:795-803.
20. Frösner G., Steffen R., Herzog C. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration. J Travel Med 2009, 16:413-419.
21. Leder K., Weller P.F., Wilson M.E. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001, 33:1553-1566.
22. Zopf Y., Rabe C., Neubert A., Janson C., Brune K., Hahn E.G., et al. Gender-based differences in drug prescription: relation to adverse drug reactions. Pharmacology 2009, 84:333-339.
23. Hewagama A., Patel D., Yarlagadda S., Strickland F.M., Richardson B.C. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009, 10:509-516.
24. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
25. Bovier P.A., Althaus B., Glueck R., Chippaux A., Loutan L. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 1999, 6:228-233.
26. Cassidy W.M., Jones G., Williams K., Deforest A., Forghani B., Virella G., et al. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health 2005, 36:187-192.